

Substitute for form 1449/PTO				<i>Complete if Known</i>	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/669,597
Sheet 1 of 1				Filing Date	September 25, 2003
				First Named Inventor	MARTINEZ, Alexa L.
				Art Unit	1654
				Examiner Name	GUPTA, Anish
				Attorney Docket Number	2057.0040002/BJD/JKM

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
/AG/	NPL9	DARO, E., <i>et al.</i> , "Polyethylene Glycol-Modified GM-CSF Expands CD11b ^{high} CD11c ^{high} But Not CD11b ^{low} CD11c ^{high} Murine Dendritic Cells <i>In Vivo</i> : A Comparative Analysis with Flt3 Ligand," <i>J. Immunol.</i> 165:49-58 (2000)			
/AG/	NPL10	GNANOU, Y., and Rempp, P., "Macromonomer synthesis. New functionalization methods," <i>Makromol. Chem.</i> 188:2111-2119 (1987)			
/AG/	NPL11	GOMBOTZ, W.R., and Pettit, D.K., "Pegylation: A Tool To Enhance Protein Delivery," <i>Polymer Prepr.</i> 40:275-276 (1999)			
/AG/	NPL12	KNÜSLI, C., <i>et al.</i> , "Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity," <i>Br. J. Haematol.</i> 82:654-663 (1992)			

859754_1.doc

Examiner Signature	/Anish Gupta/	Date Considered	3-23-09
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.